CoChat
Sign Up
Cited by 31Diabetes Treatment and ManagementRegulation of Appetite and ObesityPancreatic function and diabetes

The DOI matches its Crossref record; 295 of the 308 references it cites were found in a registry or an index.

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

Open access
AL-Noshokaty, Tohada M., Abdelhamid, Rehab, Abdelmaksoud, Nourhan M., Khaled, Aya, Hossam, Mariam, Ahmed, Razan, Saber, Toka, Khaled, Shahd, Elshaer, Shereen Saeid, Abulsoud, Ahmed I.·2025·Toxicology Reports
DOI 10.1016/j.toxrep.2025.101895PMC PMC11795145
Open this paper in CoChat — free account

Abstract

Glucagon (GCG) like peptide 1 (GLP-1) has emerged as a powerful player in regulating metabolism and a promising therapeutic target for various chronic diseases. This review delves into the physiological roles of GLP-1, exploring its impact on glucose homeostasis, insulin secretion, and satiety. We examine the compelling evidence supporting GLP-1 receptor agonists (GLP-1RAs) in managing type 2 diabetes (T2D), obesity, and other diseases. The intricate molecular mechanisms underlying GLP-1RAs are explored, including their interactions with pathways like extracellular signal-regulated kinase 1/2 (ERK1/2), activated protein kinase (AMPK), cyclic adenine monophosphate (cAMP), mitogen-activated protein kinase (MAPK), and protein kinase C (PKC). Expanding our understanding, the review investigates the potential role of GLP-1 in cancers. Also, microribonucleic acid (RNA) (miRNAs), critical regulators of gene expression, are introduced as potential modulators of GLP-1 signaling. We delve into the link between miRNAs and T2D obesity and explore specific miRNA examples influencing GLP-1R function. Finally, the review explores the rationale for seeking alternatives to GLP-1RAs and highlights natural products with promising GLP-1 modulatory effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.toxrep.2025.101895

Cites

295 of 295 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pleiotropic effects of GLP-1 [1]. [CNS: central nervous system; CVS: Cardiovascular system; GIT: Gastrointestinal tract; GLP-1R: Glucagon like peptide-1 receptor; VLDL: very low-density lipoprotein].
Fig. 1 Pleiotropic effects of GLP-1 [1]. [CNS: central nervous system; CVS: Cardiovascular system; GIT: Gastrointestinal tract; GLP-1R: Glucagon like peptide-1 receptor; VLDL: very low-density lipoprotein].CC BY-NC · PubMed Central
Fig. 2 The complex interplay between GLP-1RAs and several cellular signaling pathways. [AMPK: activated protein kinase; cAMP: cyclic adenine monophosphate; ERK 1/2: extracellular signal-regulated kinase 1/2; GLP-1R: Glucagon like peptide-1 receptor; MAPK: Mitogen-activated protein kinase; PKC: protein kinase C].
Fig. 2 The complex interplay between GLP-1RAs and several cellular signaling pathways. [AMPK: activated protein kinase; cAMP: cyclic adenine monophosphate; ERK 1/2: extracellular signal-regulated kinase 1/2; GLP-1R: Glucagon like peptide-1 receptor; MAPK: Mitogen-activated protein kinase; PKC: protein kinase C].CC BY-NC · PubMed Central
Fig. 3 Intracellular signaling through Gαs mediated by GLP-1R. [GLP-1R: Glucagon like peptide-1 receptor; ATP: adenosine triphosphate; cAMP: cyclic adenine monophosphate; Epac: exchange protein directly activated by cAMP; PKA: protein kinase A; ERK1/2: Extracellular signal-regulated kinase 1/2; AKT: protein kinase B; mTOR: Mammalian target of rapamycin; CREB: cAMP-response element binding protein].
Fig. 3 Intracellular signaling through Gαs mediated by GLP-1R. [GLP-1R: Glucagon like peptide-1 receptor; ATP: adenosine triphosphate; cAMP: cyclic adenine monophosphate; Epac: exchange protein directly activated by cAMP; PKA: protein kinase A; ERK1/2: Extracellular signal-regulated kinase 1/2; AKT: protein kinase B; mTOR: Mammalian target of rapamycin; CREB: cAMP-response element binding protein].CC BY-NC · PubMed Central
Fig. 4 GLP-1R: The Key to Unlocking Weight Loss? Exploring Potential Mechanisms [2].
Fig. 4 GLP-1R: The Key to Unlocking Weight Loss? Exploring Potential Mechanisms [2].CC BY-NC · PubMed Central
Fig. 5 The interplay between GLP-1RAs and different types of cancer.
Fig. 5 The interplay between GLP-1RAs and different types of cancer.CC BY-NC · PubMed Central
Fig. 6 A Schematic Representation of microRNA Biogenesis.
Fig. 6 A Schematic Representation of microRNA Biogenesis.CC BY-NC · PubMed Central
Fig. 7 Unveiling the hidden regulators: miRNAs and GLP-1R signaling.
Fig. 7 Unveiling the hidden regulators: miRNAs and GLP-1R signaling.CC BY-NC · PubMed Central
Fig. 8 Exploring natural products that modulate GLP-1.
Fig. 8 Exploring natural products that modulate GLP-1.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Items 201–295 of 295

Research works printed but not linked: 3

  1. Wang, 2023, GLP−1 receptor agonists for the treatment of obesity: role as a promising approach, Front. Endocrinol., 14
  2. Rowlands, 2018, Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function, Front. Endocrinol., 9, 10.3389/fendo.2018.00672 · DOI · Paper page
  3. Meloni, 2013, GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence, Diabetes Obes. Metab., 15, 15, 10.1111/j.1463-1326.2012.01663.x · DOI · Paper page

Cited by

Sorted by citations

See all 31

Related

See all

Metadata

Authors
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I.
Affiliations
  • Heliopolis University (EG)
  • Al-Azhar University (EG)
Corresponding author
Abdelhamid, Rehab
ORCID
Venue
Toxicology Reports
Publisher
Elsevier BV
Published
2025-06
Volume
14
Pages
101895
ISSN
2214-7500 (ISSN-L)
DOI
10.1016/j.toxrep.2025.101895
PMC
PMC11795145
OpenAlex
W4406560873
Cited by
30
References
308
Citations by year
2026: 16 · 2025: 14
FWCI
4.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Toxicology Reports (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, glucose homeostasis, insulin secretion, satiety, type 2 diabetes, obesity, cancer, microRNA, ERK signaling, AMPK, cAMP signaling, MAPK signaling, protein kinase C, natural products, GLP-1 signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review